Investigators at Georgetown Lombardi Comprehensive Cancer Center identified biomarkers that could represent targets for novel drugs to treat glioblastoma brain tumors. The new findings provide early evidence that there may be a benefit in targeting specific alterations in cancer cells with newer agents once a patient’s tumor becomes resistant to temozolomide.